Published in Oncologist on January 06, 2011
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies. Blood (2012) 0.95
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol (2014) 0.93
A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience (2014) 0.89
Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma (2013) 0.85
Ginseng alleviates cyclophosphamide-induced hepatotoxicity via reversing disordered homeostasis of glutathione and bile acid. Sci Rep (2015) 0.77
Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data. Med Care (2016) 0.75
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood (2009) 3.21
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol (2010) 2.51
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res (2010) 1.46
Clinical staging and prognostic markers in chronic lymphocytic leukemia. Hematol Oncol Clin North Am (2004) 0.98
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 8.11
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
Novel, acentric metal-organic coordination polymers from hydrothermal reactions involving in situ ligand synthesis. Angew Chem Int Ed Engl (2002) 7.04
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity (2004) 6.72
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity (2002) 6.27
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist (2007) 4.95
Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A (2006) 4.90
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med (2011) 3.77
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol (2010) 3.49
Synthesis of novel chiral and acentric coordination polymers by the reaction of zinc or cadmium salts with racemic 3-pyridyl-3-aminopropionic acid. Chemistry (2004) 3.49
Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity (2006) 3.41
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist (2003) 3.28
Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol (2004) 3.18
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist (2009) 3.18
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol (2003) 2.98
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res (2007) 2.94
Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst (2011) 2.74
Highly stable olefin-Cu(I) coordination oligomers and polymers. Chem Soc Rev (2005) 2.72
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med (2012) 2.69
Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res (2002) 2.56
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist (2003) 2.53
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res (2007) 2.47
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res (2004) 2.43
Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell (2010) 2.43
Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist (2009) 2.37
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
The draft genome of watermelon (Citrullus lanatus) and resequencing of 20 diverse accessions. Nat Genet (2012) 2.33
Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res (2004) 2.24
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol (2008) 2.23
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist (2007) 2.17
Large anisotropy and effect of deuteration on permittivity in an olefin copper(I) complex. Angew Chem Int Ed Engl (2007) 2.12
Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology (2012) 2.11
Do mitochondria contribute to left ventricular non-compaction cardiomyopathy? New findings from myocardium of patients with left ventricular non-compaction cardiomyopathy. Mol Genet Metab (2013) 2.08
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res (2006) 2.07
Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst (2004) 2.07
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) (2009) 2.06
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res (2002) 2.06
How to make the best use of intraoperative motor evoked potential monitoring? Experience in 1162 consecutive spinal deformity surgical procedures. Spine (Phila Pa 1976) (2014) 2.02
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist (2007) 1.94
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med (2007) 1.94
Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res (2005) 1.93
A novel GATA6 mutation in patients with tetralogy of Fallot or atrial septal defect. J Hum Genet (2010) 1.89
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84
DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog (2002) 1.83
Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest (2004) 1.82
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res (2008) 1.82
FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist (2005) 1.81
Elevated blood pressure linked to primary hyperaldosteronism and impaired vasodilation in BK channel-deficient mice. Circulation (2005) 1.80
Issues in using progression-free survival when evaluating oncology products. J Clin Oncol (2009) 1.78
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
1-[(3-Methyl-piperidin-1-yl)(phen-yl)meth-yl]-2-naphthol. Acta Crystallogr Sect E Struct Rep Online (2009) 1.72
Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov (2014) 1.70
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle (2011) 1.67
A permissive role of mushroom body α/β core neurons in long-term memory consolidation in Drosophila. Curr Biol (2012) 1.67
FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist (2005) 1.66
Can deliberately incomplete gene sample augmentation improve a phylogeny estimate for the advanced moths and butterflies (Hexapoda: Lepidoptera)? Syst Biol (2011) 1.65
IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol (2010) 1.64
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) (2009) 1.63
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res (2007) 1.62
Activity-based metabolomic profiling of enzymatic function: identification of Rv1248c as a mycobacterial 2-hydroxy-3-oxoadipate synthase. Chem Biol (2010) 1.60
Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A (2007) 1.59
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther (2008) 1.59
Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res (2008) 1.58
Cytometric detection of chromatin relaxation, an early reporter of DNA damage response. Cell Cycle (2009) 1.55
Major trends in human parasitic diseases in China. Trends Parasitol (2010) 1.54
U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist (2013) 1.52
Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013. Cancer (2014) 1.51
Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology (2010) 1.51
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist (2008) 1.49
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res (2010) 1.46
Homochiral Zn and Cd coordination polymers containing amino acid-tetrazole ligands. Inorg Chem (2003) 1.46